Acadian Asset Management
GNMX

Acadian Asset Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Acadian Asset Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-93,305
Closed -$15K – 2089
2019
Q2 		$15K Sell
93,305
-174,600
-65% -$35.3K ﹤0.01% 1620
2019
Q1 		$53K Buy
267,905
+248,476
+1,279% +$55.1K ﹤0.01% 1658
2018
Q4 		$14K Hold
19,429
– – ﹤0.01% 1588
2018
Q3 		$24K Hold
19,429
– – ﹤0.01% 1493
2018
Q2 		$22K Buy
+19,429
New +$29.5K ﹤0.01% 1521
2015
Q3 		– Sell
-711
Closed -$4K – 1503
2015
Q2 		$4K Buy
+711
New +$5.51K ﹤0.01% 1295

Other funds holding GNMX

AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $640M AUM 26.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Acadian Asset Management's GNMX Position: Q3 2019 in Review

Acadian Asset Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2019, closing a stake of 93,305 shares — an estimated $15K sold.

Acadian Asset Management first reported a position in GNMX in Q2 2015 and held it in 6 quarters. The position peaked at $53K in Q1 2019. 25 funds tracked by Wall St. Rank hold GNMX as of Q3 2019.

  • Acadian Asset Management reported no remaining Aevi Genomic Medicine Inc position as of Q3 2019 after selling out during the quarter.
  • Acadian Asset Management sold 93,305 Aevi Genomic Medicine Inc shares in Q3 2019, an estimated $15K.
  • Acadian Asset Management first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 6 quarters.
  • Acadian Asset Management's Aevi Genomic Medicine Inc position peaked at $53K in Q1 2019.
  • 25 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2019.

Based on Acadian Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.